You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

93 Results
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer
New Drug Funding Program
    Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer
Aug 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Palliative
Sep 2019
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019
Guidelines and Advice
Regimen
Drug
Other Name(s): Afinitor®
Updated
Dec 2025
Drug
Other Name(s): Elrexfio™
Updated
Dec 2025
Drug
Other Name(s): Epkinly™
Oct 2025
Drug
Other Name(s): Braftovi®
Apr 2024
Drug
Other Name(s): Pharmorubicin PFS®
Apr 2023

Pages